广西师范大学学报（自然科学版） ›› 2026, Vol. 44 ›› Issue (6): 195-210.doi: 10.16088/j.issn.1001-6600.2026011302

• 药用资源研究 • 上一篇    下一篇

整合UPLC-QTRAP-MS/MS、网络药理学与细胞实验探讨调气柔肝散结丸抗肝癌血管生成及转移的分子机制

吴黎川1,2,3, 孙轶琳1,2, 谢雨心1,2, 秦健峰4,5, 许立拔4, 龙富立6*, 韦金锐3,4*   

  1. 1.广西大学 医学院, 广西 南宁 530004;
    2.广西特色生物医药重点实验室(广西大学), 广西 南宁 530004;
    3.广西高校中医临床研究重点实验室(广西中医药大学), 广西 南宁 530024;
    4.广西中医药大学 中医药壮瑶医药研究院, 广西 南宁 530200;
    5.广西中药药效研究重点实验室(广西中医药大学), 广西 南宁 530200;
    6.广西中医药大学 第一附属医院, 广西 南宁 530023
  • 收稿日期:2026-01-13 修回日期:2026-03-09 出版日期:2026-11-05 发布日期:2026-11-10
  • 通讯作者: 韦金锐(1987—),女,广西南宁人,广西中医药大学助理研究员,博士。E-mail: weijr@gxtcmu.edu.cn龙富立(1981—), 男, 广西桂林人, 广西中医药大学第一附属医院主任医师, 博导。E-mail: longfuli005@163.com
  • 基金资助:
    广西自然科学基金(2025GXNSFBA069425);广西高校中医临床研究重点实验室开放课题(GXHC-MBTCM-07, GXHC-MBTCM-02, GXED-CMCR-02)

Integrating UPLC-QTRAP-MS/MS, network pharmacology, and cellular assays to investigate the molecular mechanism of Tiaoqi Rougan Sanjie Pill in inhibiting angiogenesis and metastasis of hepatocellular carcinoma

Wu Lichuan1,2,3, Sun Yilin1,2, Xie Yuxin1,2, Qin Jianfeng4,5, Xu Liba4, LongFuli6*, Wei Jinrui3,4*   

  1. 1. School of Medicine, Guangxi University, Nanning Guangxi 530004, China;
    2. Guangxi Key Laboratory of Special Biomedicine (Guangxi University), Nanning Guangxi 530004, China;
    3. Guangxi University Key Laboratory of Chinese Medicine Clinical Research (Guangxi University of Chinese Medicine), Nanning Guangxi 530024, China;
    4. Institute of Traditional Chinese and Zhuang-Yao Ethnic Medicine, Guangxi University of Chinese Medicine, Nanning Guangxi 530200, China;
    5. Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica (Guangxi University of Chinese Medicine), Nanning Guangxi 530200, China;
    6. The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning Guangxi 530023, China
  • Received:2026-01-13 Revised:2026-03-09 Online:2026-11-05 Published:2026-11-10

摘要： 本文旨在探讨调气柔肝散结丸(Tiaoqi Rougan Sanjie Pill, TRSP)体外抑制肝癌血管形成、迁移和侵袭的活性成分及分子机制。通过超高效液相色谱-四极杆-线性离子阱-串联质谱仪( ultra performance liquid chromatography-quadrupole linear ion trap-tandem mass spectrometry, UPLC-QTRAP-MS/MS)技术从TRSP中鉴定出42个化学成分,基于网络药理学筛选得到128个与肝癌转移相关的潜在靶点,经拓扑学分析筛选出HIF-1α、TNF、CASP3和SRC等4个核心靶点,其中HIF-1α居于网络关键位置。分子对接显示,TRSP中多个成分与HIF-1α具有良好的结合活性,结合能均低于-20.9 kJ/mol。体外实验证实,TRSP可剂量依赖性地抑制肝癌细胞(HepG2和MHCC-97H)的增殖、迁移与侵袭,并显著抑制人脐静脉内皮细胞(HUVECs)的血管生成能力。机制研究表明,TRSP能下调肝癌细胞中HIF-1α及其下游因子VEGFA的蛋白表达。综上所述,TRSP可能通过抑制HIF-1α/VEGF信号通路,发挥抗血管生成及抗肝癌转移作用,本研究为其临床应用提供了实验依据。

关键词: 调气柔肝散结丸, 肝癌, 血管形成, 迁移, 侵袭, HIF-1α/VEGF信号通路

Abstract: This study aimed to investigate the active components and molecular mechanism of Tiaoqi Rougan Sanjie Pill (TRSP) in inhibiting angiogenesis, migration and invasion of hepatocellular carcinoma in vitro. A total of 42 chemical components were identified by UPLC-QTRAP-MS/MS; furthermore, based on network pharmacology, 128 potential targets related to HCC metastasis were screened, and four core targets (HIF-1α, TNF, CASP3, and SRC) were identified by topological analysis, with HIF-1α occupying a central position in the network and being identified as the core target. Molecular docking showed that multiple components in TRSP exhibited good binding activity with HIF-1α, with binding energies all below -20.9 kJ/mol. In vitro experiments confirmed that TRSP dose-dependently inhibited the proliferation, migration and invasion of hepatoma cells (HepG2 and MHCC-97H), and significantly suppressed the angiogenic ability of human umbilical vein endothelial cells (HUVECs). Mechanistic studies revealed that TRSP downregulated the protein expression of HIF-1α and its downstream factor VEGFA in hepatoma cells. In conclusion, TRSP may exert anti-angiogenic and anti-metastatic effects against HCC by inhibiting the HIF-1α/VEGF signaling pathway, providing experimental evidence for its clinical application.

Key words: Tiaoqi Rougan Sanjie Pills, liver cancer, angiogenesis, migration, invasion, HIF-1α/VEGF signaling pathway

中图分类号:  R285

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a Cancer Journal for Clinicians, 2024, 74(3): 229-263. DOI:10.3322/caac.21834.
[2] Zhou J, Sun H C, Wang Z, et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 ed.)[J]. Liver Cancer, 2025, 14(6): 779-835. DOI: 10.1159/000546574.
[3] Zhou J, Sun H C, Wang Z, et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 ed.)[J]. Liver Cancer, 2023, 12(5): 405-444. DOI: 10.1159/000530495.
[4] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 协和医学杂志, 2024, 15(3): 532-558. DOI: 10.12290/xhyxzz.2024-0304.
[5] Wang K L, Chen Q, Shao Y Y, et al. Anticancer activities of TCM and their active components against tumor metastasis[J]. Biomedicine & Pharmacotherapy, 2021, 133: 111044. DOI: 10.1016/j.biopha.2020.111044.
[6] Liu Y M, Li X Q, Zhang X R, et al. Uncovering the key pharmacodynamic material basis and possible molecular mechanism of extract of Epimedium against liver cancer through a comprehensive investigation[J]. Journal of Ethnopharmacology, 2023, 317: 116765. DOI: 10.1016/j.jep.2023.116765.
[7] Tian X C, Liu F, Wang Z J, et al. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway[J]. Journal of Ethnopharmacology, 2024, 322: 117577. DOI: 10.1016/j.jep.2023.117577.
[8] 于春, 高芬, 郑兰兰, 等. 肝癌相关信号通路的中药调控研究进展[J]. 中国实验方剂学杂志, 2024, 30(15): 232-243. DOI: 10.13422/j.cnki.syfjx.20240128.
[9] 吴黎川, 谈振凯, 覃业浩, 等. 槐定碱衍生物抑制肝癌细胞迁移与侵袭研究[J]. 广西师范大学学报(自然科学版), 2025, 43(2): 207-220. DOI: 10.16088/j.issn.1001-6600.2024061801.
[10]覃业浩, 郭晨静, 吴黎川, 等. 基于UPLC-QTOF-MS、网络药理学和实验验证探讨复方鹿仙草颗粒抗肝癌作用机制[J]. 广西师范大学学报(自然科学版), 2025, 43(2): 221-237. DOI: 10.16088/j.issn.1001-6600.2024080505.
[11]Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: a therapeutic target[J]. World Journal of Gastroenterology, 2015, 21(42): 12171-12178. DOI: 10.3748/wjg.v21.i42.12171.
[12]Méndez-Blanco C, Fondevila F, García-Palomo A, et al. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors[J]. Experimental & Molecular Medicine, 2018, 50(10): 1-9. DOI: 10.1038/s12276-018-0159-1.
[13]Pandey P, Lakhanpal S, Mahmood D, et al. Recent update of natural compounds as HIF-1α inhibitors in colorectal carcinoma[J]. Drug Design, Development and Therapy, 2025, 19: 2017-2034. DOI: 10.2147/DDDT.S511406.
[14]庞娣, 王德, 林镛, 等. 龙富立调气论治原发性肝癌的经验总结[J]. 中西医结合肝病杂志, 2025, 35(3): 367-369. DOI: 10.3969/j.issn.1005-0264.2025.03.022.
[15]刘志芳. 柔肝散结丸联合HAIC术治疗气滞血瘀型PLC患者的临床疗效研究[D]. 南宁: 广西中医药大学, 2024.
[16]班少群. 柔肝散结丸治疗气滞血瘀型PLC患者TACE术后的临床研究[D]. 南宁: 广西中医药大学, 2023.
[17]梅梦如. 柔肝散结丸联合仑伐替尼治疗气滞血瘀型原发性肝癌的临床观察[D]. 南宁: 广西中医药大学, 2024.
[18]张天一, 王慧, 何孝忠, 等. 首荟通便胶囊通过调控TLR4/MyD88/NF-κB信号通路抑制幽门螺杆菌诱导的炎症反应[J]. 中草药, 2025, 56(24): 9055-9062. DOI: 10.7501/j.issn.0253-2670.2025.24.017.
[19]郭孝武. 超声提取与常规提取对部分中药碱类成分提出率的比较[J]. 世界科学技术-中药现代化, 2002, 4(5): 59-61. DOI: 10.3969/j.issn.1674-3849.2002.05.012.
[20]张晓东, 潘国凤, 吕圭源. 超声提取在中药化学成分提取中的应用研究进展[J]. 时珍国医国药, 2004, 15(12): 861-862. DOI: 10.3969/j.issn.1008-0805.2004.12.054.
[21]Liu H F, Liu Z T, Xie P T, et al. LRRC1 promotes angiogenesis through regulating AKT/GSK3β/β-catenin/VEGFA signaling pathway in hepatocellular carcinoma[J]. Cells, 2025, 14(23): 1919. DOI: 10.3390/cells14231919.
[22]Magar A G, Morya V K, Noh K C. Molecular crosstalk between RUNX2 and HIF-1α in osteosarcoma: implications for angiogenesis, metastasis, and therapy resistance[J]. International Journal of Molecular Sciences, 2025, 26(15): 7642. DOI: 10.3390/ijms26157642.
[23]Almanzar G, Alarcon J C, Garzon R, et al. Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease: a link between cancer and autoimmunity[J]. Frontiers in Immunology, 2025, 16: 1633845. DOI: 10.3389/fimmu.2025.1633845.
[24]Yang X M, Chen W C, Sun H T, et al. Baicalin promotes anti-tumor immunity in hepatocellular carcinoma through HIF-1α/Lactate/CXCL9 axis[J]. Biochemical Pharmacology, 2025, 241: 117157. DOI: 10.1016/j.bcp.2025.117157.
[25]Lluis J M, Buricchi F, Chiarugi P, et al. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-kappaB via c-SRC and oxidant-dependent cell death[J]. Cancer Research, 2007, 67(15): 7368-7377. DOI: 10.1158/0008-5472.CAN-07-0515.
[26]Cai H X, Hu Q, Song Z Y, et al. Liuwei Dihuang pills suppress hepatocellular carcinoma via PI3K/AKT/TP53 pathway: integrating network pharmacology, metabolomics, and experimental validation[J]. Phytomedicine, 2026, 152: 157780. DOI: 10.1016/j.phymed.2026.157780.
[27]Zheng Z M, Du Y Z, Jiang H, et al. KAJF alleviated colorectal cancer liver metastasis by reshaping the gut microbiota and inhibiting M2-like macrophage polarization[J]. Phytomedicine, 2025, 142: 156766. DOI: 10.1016/j.phymed.2025.156766.
[28]Hu S N, Li S M, Xu Y Z, et al. The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/Akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation[J]. Phytomedicine, 2024, 128: 155488. DOI: 10.1016/j.phymed.2024.155488.
[29]Zhu X Y, Li Z W, Chen L, et al. Exosomes delivering miR-129-5p combined with sorafenib ameliorate hepatocellular carcinoma progression via the KCTD1/HIF-1α/VEGFpathway[J]. Cellular Oncology, 2025, 48(3): 743-760. DOI: 10.1007/s13402-025-01044-x.
[30]Zhu L Y, Ao L, Guo Z T, et al. Recombinant canstatin inhibits the progression of hepatocellular carcinoma by repressing the HIF-1α/VEGF signaling pathway[J]. Biomedicine & Pharmacotherapy, 2024, 179: 117423. DOI: 10.1016/j.biopha.2024.117423.
[31]Albulescu L, Suciu A, Neagu M, et al. Differential biological effects of Trifolium pratense extracts: in vitro studies on breast cancer models[J]. Antioxidants, 2024, 13(12): 1435. DOI: 10.3390/antiox13121435.
[32]Jodynis-Liebert J, Kujawska M. Biphasic dose-response induced by phytochemicals: experimental evidence[J]. Journal of Clinical Medicine, 2020, 9(3): 718. DOI: 10.3390/jcm9030718.
[33]Liu X R, Zhang J, Yi T, et al. Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies[J]. Biomarker Research, 2025, 13(1): 62. DOI: 10.1186/s40364-025-00779-x.
[34]Magar A G, Morya V K, Kwak M K, et al. A molecular perspective on HIF-1α and angiogenic stimulator networks and their role in solid tumors: anupdate[J]. International Journal of Molecular Sciences, 2024, 25(6): 3313. DOI: 10.3390/ijms25063313.
[35]曾元莲, 于少朋, 胥亦, 等. 中药调控HIF-1α抑制肝癌的研究进展[J]. 中药与临床, 2020, 11(2): 65-70.
[36]Chen J B, Wu C Q, Yu K, et al. Bufalin targets the SRC-3/c-Myc pathway in chemoresistant cells to regulate metastasis induced by chemoresistance in colorectal cancer[J]. Journal of Cancer Research and Clinical Oncology, 2025, 151(2): 71. DOI: 10.1007/s00432-025-06124-x.
[37]Feng X, Yu Y, He S J, et al. Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism[J]. Cancer Letters, 2017, 385: 12-20. DOI: 10.1016/j.canlet.2016.10.042.
[38]Mei X Y, Ouyang H, Zhang H, et al. Scutellarin suppresses the metastasis of triple-negative breast cancer via targeting TNFα/TNFR2-RUNX1-triggered G-CSF expression in endothelial cells[J]. Biochemical Pharmacology, 2023, 217: 115808. DOI: 10.1016/j.bcp.2023.115808.
[39]Ma Y, Pan Y, Zhao Q C, et al. Exploring the therapeutic potential and in vitro validation of baicalin for the treatment of triple-negative breast cancer[J]. Frontiers in Pharmacology, 2025, 16: 1530056. DOI: 10.3389/fphar.2025.1530056.
[40]Yu W J, Peng Z Z, Lü B W, et al. Tanshinone ⅡA attenuates airway inflammation and airway remodeling in bronchial asthma by inhibiting p38/NF-κB and AKT/HIF-1α[J]. Journal of Asthma, 2026, 63(4): 428-438. DOI: 10.1080/02770903.2025.2603318.
[41]Ho I, Xie Y J, Liu Z P, et al. Atlas-based mapping of traditional Chinese medicine effects on tumor microcirculation regulation[J]. Immunity, Inflammation and Disease, 2026, 14(2): e70347. DOI: 10.1002/iid3.70347.
[42]Mei X Y, Zhou L Y, Zhang T Y, et al. Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF-mediated retinal neoangiogenesis[J]. Vascular Pharmacology, 2018, 101: 29-37. DOI: 10.1016/j.vph.2017.11.002.
[43]Lee M S, Lee S O, Kim K R, et al. Sphingosine kinase-1 involves the inhibitory action of HIF-1α by chlorogenic acid in hypoxic DU145 cells[J]. International Journal of Molecular Sciences, 2017, 18(2): 325. DOI: 10.3390/ijms18020325.
[44]Mao X W, Pan C S, Huang P, et al. Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: involvement ofSRC kinase[J]. Scientific Reports, 2015, 5: 11155. DOI: 10.1038/srep11155.
[45]邓桂明, 向彪, 肖小芹, 等. 基于网络药理学的乌药主要化学成分药效作用研究[J]. 中草药, 2018, 49(21): 5125-5133. DOI: 10.7501/j.issn.0253-2670.2018.21.025.
[46]Matos R C, Bitencourt A F A, Santana P A L, et al. Phytochemical profile and biological activities of the hydroethanolic extract of Pouteria guianensis: a pharmacological investigation[J]. Journal of Ethnopharmacology, 2025, 348: 119818. DOI: 10.1016/j.jep.2025.119818.
[47]Acuña-Pilarte K, Koh M Y. The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation[J]. Trends in Biochemical Sciences, 2025, 50(8): 677-694. DOI: 10.1016/j.tibs.2025.06.005.
[48]Liu B X, Xie Y, Zhang J Y, et al. SERPINB5 promotes colorectal cancer invasion and migration by promoting EMT and angiogenesis via the TNF-α/NF-κB pathway[J]. International Immunopharmacology, 2024, 131: 111759. DOI: 10.1016/j.intimp.2024.111759.
[49]Ramos H, Calheiros J, Almeida J, et al. SLMP53-1 inhibits tumor cell growth through regulation of glucose metabolism and angiogenesis in a P53-dependent manner[J]. International Journal of Molecular Sciences, 2020, 21(2): 596. DOI: 10.3390/ijms21020596.
[50]Nie C H, Wang B, Wang B Q, et al. Protopine triggers apoptosis via the intrinsic pathway and regulation of ROS/PI3K/Akt signalling pathway in liver carcinoma[J]. Cancer Cell International, 2021, 21(1): 396. DOI: 10.1186/s12935-021-02105-5.
[1] 谢文彬, 喻宇慧, 禹海双, 邬慧贤, 金俊飞, 陈振锋, 卢幸. 草酰胺衍生物Z21对人肝癌细胞株Hep G2的体外抗肿瘤活性研究[J]. 广西师范大学学报（自然科学版）, 2025, 43(6): 162-173.
[2] 刘俊杰, 马凯, 黄泽华, 田苗, 邱芹军, 陶留锋, 谢忠. 基于迁移学习及通道先验注意力机制的地质构造识别[J]. 广西师范大学学报（自然科学版）, 2025, 43(2): 107-120.
[3] 吴黎川, 谈振凯, 覃业浩, 赵续棋, 谢雨心, 黄丽羽, 韦金锐. 槐定碱衍生物抑制肝癌细胞迁移与侵袭研究[J]. 广西师范大学学报（自然科学版）, 2025, 43(2): 207-220.
[4] 覃业浩, 郭晨静, 吴黎川, 魏鹏程. 基于UPLC-QTOF-MS、网络药理学和实验验证探讨复方鹿仙草颗粒抗肝癌作用机制[J]. 广西师范大学学报（自然科学版）, 2025, 43(2): 221-237.
[5] 李欣, 宁静. 基于时空特征融合的电力系统暂态稳定评估[J]. 广西师范大学学报（自然科学版）, 2024, 42(6): 89-100.
[6] 蒋懿波, 刘会家, 吴田. 基于改进残差网络的输电线路雷击过电压识别研究[J]. 广西师范大学学报（自然科学版）, 2023, 41(4): 74-83.
[7] 牛学德, 高丙朋, 任荣荣, 徐明明. 基于轻量级CNN的作物病虫害识别及安卓端应用[J]. 广西师范大学学报（自然科学版）, 2022, 40(6): 59-68.
[8] 田晟, 宋霖. 基于CNN和Bagging集成的交通标志识别[J]. 广西师范大学学报（自然科学版）, 2022, 40(4): 35-46.
[9] 徐王军, 曹进德, 伍代勇, 申传胜. 一类具有迁移和Allee效应的食饵-捕食者系统稳定性[J]. 广西师范大学学报（自然科学版）, 2022, 40(2): 103-115.
[10] 李银玲, 周晶, 陈莹, 陈俏媛, 林万华. Sdr9c7基因在荷瘤小鼠红细胞中异常表达的研究[J]. 广西师范大学学报（自然科学版）, 2021, 39(6): 147-153.
[11] 白捷, 高海力, 王永众, 杨来邦, 项晓航, 楼雄伟. 基于多路特征融合的Faster R-CNN与迁移学习的学生课堂行为检测[J]. 广西师范大学学报（自然科学版）, 2020, 38(5): 1-11.
[12] 严浩, 许洪波, 沈英汉, 程学旗. 开放式中文事件检测研究[J]. 广西师范大学学报（自然科学版）, 2020, 38(2): 64-71.
[13] 霍群, 刘杰, 陈莉, 廖维甲. 血清AFP临界值判断对肝癌诊断的影响[J]. 广西师范大学学报（自然科学版）, 2014, 32(3): 121-124.
[14] 王桂芝, 吕肖君, 陆金帅, 李洁. 基于AHM算法的流动人口迁移满意度研究[J]. 广西师范大学学报（自然科学版）, 2013, 31(2): 7-12.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 广西师范大学学报（自然科学版）编辑部
地址：广西桂林市三里店育才路15号　邮编：541004
电话：0773-5857325　E-mail: gxsdzkb@mailbox.gxnu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发